FDA launches its own AI to speed up clinical reviews and scientific evaluations
FDA has launched ELSA, a generative AI tool for a range of agencies, to help its employees deliver everything from clinical reviews to surveys. Of course, we live in a period of extensive disinformation and a counterattack against science, but why not rush with AI?
Elsa – Yes, it’s weird, like from the Queen of Snow freezing – Completed “Very Successful Pilot Program with FDA’s Scientific Reviewers”. According to the FDA, AI tools can help read, write and summarize everything from adverse events to assessments. Elsa can also perform tag comparisons and generate code. It has been used to speed up clinical protocol review and scientific evaluation and to find “high priority examination goals.”
Elsa should The FDA pointed out to be a safe platform. It is not clear how the agency trains ELSA exactly, but the FDA claims this is not through “data submitted by a regulated industry.” This information exists in GovCloud of Amazon Web Services, and this information should again retain all information.
The FDA calls Elsa the first step in her AI journey. “Now with the release of ELSA, AI is no longer an out of reach commitment, but a dynamic force that enhances and optimizes the performance and potential of each employee,” said Jeremy Walsh, chief AI officer of the FDA. “When we understand how employees use the tool, our development team will be able to add functionality and grow with the demands of employees and agents.”
If you purchase something through the links in this article, we may earn commissions.
